Alfred E. Slanetz, Ph.D. – Dr. Slanetz is the founder of the Company and has been President, Chief Executive Officer and a director of the Company full time since its inception. Prior to co-founding the Company, he served as Chief Executive Officer and President of Genetix Pharmaceuticals, Inc. Dr. Slanetz served as Vice President, Business Development of TRANSGENE in May 1996. From 1994 to 1996, he served as Manager, New Product Planning and Development at Genentech Inc. Prior to that, Dr. Slanetz was a Management Consultant for Arthur D. Little. He received his Ph.D. in Molecular and Immunobiology from Yale University.
Terry Y Nakagawa, Ph.D. – Dr. Nakagawa is the head of the Company’s Research and Development Programs. Prior to joining the Company, she served as Assistant Director at the Astellas Research Institute of America as the leader of drug discovery programs targeting autoimmunity and transplantation. With over twenty years of research experience, Dr. Nakagawa has held various scientific positions at Abbott Laboratories, Dendreon, the University of Washington, and Northwestern University. She received her Ph.D. in Immunobiology from Yale University.
Francis E. Kenny, M.S. – Mr. Kenny has been with the Company since its inception as the Manager of Process Development. Prior to joining the Company, he worked at bluebird bio as Senior Scientist in Process and Product Development of Lenti-D, a lentivirus vector for gene therapy of Adrenoleukodystrophy and Lentiglobin, a lentivirus vector for gene therapy of Sickle Cell Anemia and β-thalassemia. Prior to bluebird bio, Mr. Kenny has held positions at Lonza Biologics, Celldex Therapeutics, Massachusetts Public Health Biologic Laboratories, Verax Biomedical, Bayer Diagnostics and AMAG Pharmaceuticals. He received his M.S. in Microbiology from the University of Rhode Island and his B.S. in Microbiology from the University of Massachusetts, Amherst.
Jason Sager, M.D. – Dr. Sager joined the Company as Head of clinical development. He is an accomplished physician-scientist with 12 years of clinical practice at Johns Hopkins Hospital and the Dana Farber Cancer Institute as well as 9 years of translational drug development experience at Genentech, Novartis, and Sanofi, where he held the title of US Head of Oncology Early Clinical Development. He received his M.D. from Cornell University, trained as a pediatric oncologist at Johns Hopkins and the NCI with the renowned cancer biologist Bert Vogelstein. In 2014 he founded Sagely Health, a company dedicated to guiding cancer patients.
Fredrik Buch, M.D. – Dr. Buch joined the Company as Managing Director operations in Stockholm, Sweden. He was previously SVP, Clinical Development Pharmacia; VP, Clinical Scandinavia, Bristol Myers Squibb; Partner, HealthCap, a Development Officer, Karolinska Institute and a Practicing Clinician.
Steven Kloeblen, M.B.A., C.M.A. – Mr. Kloeblen serves on the company’s Board of Directors. With more than 20 years of leadership experience, Mr. Kloeblen has served in numerous positions during his extensive career at IBM as Controller, Chief Information Officer, Vice President, CFO, and COO. He is currently the Regional Director and Partner at the CFO Center, Jacksonville, FL. He received his Master of Business Administration in Finance from Pace University and Bachelor of Science in Accounting from Villanova University.
Medical Advisors & Collaborators
Our preclinical and clinical development program is advised by the following team of leading scientists and physicians:
Jody Baron, M.D., Ph.D., Medical Advisor; Professor of Medicine, University of California San Francisco
Marco Davila, M.D., Ph.D., Medical Advisor; Director, Adoptive Cell Therapy Center, Moffitt Cancer Center
Julian Kim, M.D., Medical Advisor;Chief Medical Officer, Case Western Reserve University Cancer Center
Markus Maeurer, M.D., Ph.D., Professor, Head Division Therapeutic Immunology, Karolinska Institute
Fred Wang, M.D., Medical Advisor; Professor of Medicine, Harvard Medical School